Selvin, E., S. Marinopoulos, G. Berkenblit, T. Rami, F. L. Brancati, N. R. Powe, and S. H. Golden. 2004.  Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Annals of Internal Medicine 141(6):421-431.

Siegel, J. P. 2002. Assessing the use of activated protein C in the treatment of severe sepsis. New England Journal of Medicine 347(13):1030-1034.

Steel-Fisher, G. K., R. J. Blendon, M. M. Bekheit, and K. Lubell. 2010. The public’s response to the 2009 H1N1 influenza pandemic. New England Journal of Medicine 362(22):e65(1)-e65(6).

Straus, S. E., P. Paul Glasziou, W. S. W. Scott Richardson, and R. B. R. Brian Haynes. 2010. Evidence-based medicine: How to practice and teach it, 4th edition. Edinburgh: Churchill Livingstone.

Strickland, A. A., C. S. Taber, and M. Lodge. 2011. Motivated reasoning and public opinion. Journal of Health Politics, Policy and Law 36(6):935-944.

Temple, R. 1999. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 282(8):790-795.

Temple, R., and G. W. Pledger. 1980. The FDA’s critique of the anturane reinfarction trial. New England Journal of Medicine 303(25):1488-1492.

Tonkin, A. M., and L. Chen. 2010. Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 122(8):850-852.

Transparency Task Force, HHS, and FDA. 2010. FDA transparency initiative: Draft proposals for public comments regarding disclosure policies of the U.S. Food and Drug Administration. Washington, DC: Department of Health and Human Services.

Wilson, P. W. 2008. Cardiovascular risk assessment—where are we going? Preventive Cardiology 11(3):183-184.

Woodcock, J., J. M. Sharfstein, and M. Hamburg. 2010. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. New England Journal of Medicine 363(16):1489-1491.

Yu, D. T., D. L. Seger, K. E. Lasser, A. S. Karson, J. M. Fiskio, A. C. Seger, and D. W. Bates. 2011. Impact of implementing alerts about medication black-box warnings in electronic health records. Pharmacoepidemiology and Drug Safety 20(2):192-202.

The National Academies of Sciences, Engineering, and Medicine
500 Fifth St. N.W. | Washington, D.C. 20001

Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement